Cell-penetrating peptides: Mechanisms and applications

Current Pharmaceutical Design

Volumn 11, Issue 28, 2005, Pages 3597-3611

  El Andaloussi, S ^a   Holm, T ^a   Langel, Ülo ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Cargo delivery; Cell penetrating peptides; Endocytosis; Protein transduction; Transportan

Indexed keywords

AVIDIN; BETA GALACTOSIDASE; CARRIER PROTEIN; CASPASE 3; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CELL PENETRATING PEPTIDE; CLATHRIN; CRE RECOMBINASE; CYCLOSPORIN A; ENHANCED GREEN FLUORESCENT PROTEIN; GALANIN RECEPTOR 1; GLYCOSAMINOGLYCAN; I KAPPA B KINASE INHIBITOR; INFLUENZA VIRUS HEMAGGLUTININ; MELITTIN; PENETRATIN; PEPTIDE; PEPTIDE NUCLEIC ACID; PLASMID DNA; POLO LIKE KINASE 1; PROTEIN BCL XL; PROTEIN VP22; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; TACROLIMUS; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSFERRIN; TRANSPORTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL TRANSPLANTATION; DENDRITIC CELL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME INHIBITION; EXPRESSION VECTOR; FLUORESCENCE ACTIVATED CELL SORTER; GENE THERAPY; GENE VECTOR; GENETIC RECOMBINATION; GRAFT REJECTION; HUMAN; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BILAYER; LIPID MEMBRANE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANCREAS ISLET; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC VECTORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; RNA, SMALL INTERFERING;

EID: 27744557054     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580796     Document Type: Review

References (135)

1. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422: 37-44.
2. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-42.
3. Weiner AL. Liposomes for protein delivery: selecting manufacture and development processes. Immunomethods 1994; 4: 201-9.
4. Wearley LL. Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst 1991; 8: 331-94.
5. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18: 33-7.
6. Lindgren M, Hällbrink M, Prochiantz A, Langel Ü. Cell-penetrating peptides. Trends Pharmacol Sci 2000; 21: 99-103.
7. Langel Ü. Cell-Penetrating Peptides: Processes and Applications, CRC Press: Boca Raton, FL 2002.
8. Järver P, Langel Ü. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 2004; 9: 395-402.
9. Richard JP, Melikov K, Vivés E, Ramos C, Verbeure B, Gait MJ, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003; 278: 585-90.
10. Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, Beltram F, el al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 2003; 278: 34141-9.
11. Lundberg M, Johansson M. Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun 2002; 291: 367-71.
12. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988; 55: 1179-88.
13. Vivés E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-7.
14. Joliot AH, Triller A, Volovitch M, Pernelle C, Prochiantz A. alpha-2,8-Polysialic acid is the neuronal surface receptor of antennapedia homeobox peptide. New Biol 199 1; 3: 1121-34.
15. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-50.
16. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-33.
17. Pooga M, Hallbrink M, Zorko M, Langel 0. Cell penetration by transportan. FASEB J 1998; 12: 67-77.
18. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 1997; 25: 2730-6.
19. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 2000; 6: 1253-7.
20. Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, et al. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar. compounds into the cell interior non-endocytically. Biochim Biophys Acta 1998; 1414: 127-39.
21. Hällibrink M, Florén A, Elmquist A, Pooga M, Bartfai T, Langel Ü. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 200 1; 1515: 101-9.
22. Soomets U, Lindgren M, Gallet X, Hällbrink M, Elmquist A, Balaspiri L, et al. Deletion analogues of transportan. Biochim Biophys Acta 2000; 1467: 165-76.
23. Lindgren M, Gallet X, Soomets U, Hällbrink M, Brk̊enhielm E, Pooga K et al. Translocation properties of novel cell penetrating transportan and penetratin analogues. Bioconjug Chem 2000; 11: 619-26.
24. Howl J, Jones S, Farquhar M. Intracellular delivery of bioactive peptides to RBL-21-13 cells induces beta-hexosaminidase secretion and phospholipase D activation. Chembiochem 2003; 4: 1312-6.
25. Drin G, Mazel M, Clair P, Mathieu D, Kaczorek M, Temsamani J. Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinity. Eur J Biochem 2001; 268: 1304-14.
26. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 2000; 97: 13003-8.
27. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000; 56: 318-25.
28. Elmquist A, Lindgren M, Bartfai T, Langel Ü. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res 2001; 269: 23744.
29. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996; 271: 18188-93.
30. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001; 276: 5836-40.
31. Oren Z, Shai Y. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 1998; 47: 451-63.
32. Matsuzaki K, Yoneyama S, Miyajima K. Pore formation and translocation of melittin. Biophys J 1997; 73: 931-8.
33. Thorën PE, Persson D, Isakson P, Goksor M, Önfelt A, Norden B. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem Biophys Res Commum 2003; 307: 100-7.
34. Lundberg M, Wikstr6m S, Johansson M. Cell surface adherence and endocytosis of protein transduction domains. Mol Ther 2003; 8:143-50.
35. Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F. Caveolae-mediated internalization of extracellular HIV-I tat Ilision proteins visualized in real time. Mol Ther 2003; 8: 284-94.
36. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 2003; 278: 31192-201.
37. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-IIA fusogenic peptide enhances escape of TAT-fasion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-5.
38. Sandgren S, Wittrup A, Cheng F, Jonsson M, Eklund E, Busch S, et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004; 279: 17951-6.
39. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 2003; 278: 35109-14.
40. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglyzans. J Biol Chem 200 1; 276: 3254-61.
41. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002; 277: 2437-43.
42. Fuchs SM, Raines RT. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004; 43: 2434-44.
43. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem SO 2003; 28: 145-51.
44. Violini S, Sharma V, Prior JL, Dyszlewski M, Piwnica-Worms D. Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate. Biochemistry 2002; 41: 12652-61.
45. Koppelhus U, Awasthi SK, Zachar V, Hoist HU, Ebbesen P, Nielsen PE. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev 2002; 12: 51-63.
46. Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, Orlov SV, et al. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem 2003; 278: 42625-36.
47. Christiaens B, Grooten J, Reusens M, Joliot A, Goethals M, Vandekerckhove J, et al. Membrane interaction and cellular internalization of penetratin peptides. Eur J Biochem 2004; 271: 1187-97.
48. Deshayes S, Heitz A, Morris MC, Charnet P, Divita G, Heitz F. Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-I through conformational analysis. Biochemistry 2004; 43: 1449-57.
49. Henriques ST, Castanho MA. Consequences of nonlytic membrane perturbation to the translocation of the cell penetrating peptide pep-1 in lipidic vesicles. Biochemistry 2004; 43: 9716-24.
50. Falnes PO, Wesche J, Olsnes S. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 2001; 40: 4349-58.
51. Silhol M, Tyagi M, Giacca M, Lebleu B, Vives E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur J Biochem 2002; 269: 494-501.
52. Hariton-Gazal E, Rosenbluh J, Graessmann A, Gilon C, Loyter A. Direct translocation of histone molecules across cell membranes. J Cell Sci 2003; 116: 4577-86.
53. Säälik P, Elmquist A, Hansen M, Padari K, Saar K, Vilit K, et al. Protein Cargo Delivery Properties of Cell-Penetrating Peptides. A Comparative Study. Bioconjug Chem 2004; in press.
54. Lindgren ME, Hällbrink MM, Elmquist AM, Langet Ü. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem 12004; 377: 69-76.
55. Dietz GP, Bdeltahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004; 27: 85-131.
56. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;, 91: 664-8.
57. Lindsay MA. Peptide-mediated cell delivery: application in protein target validation. Curr Opin Pharmacol 2002; 2: 587-94.
58. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 2002; 22: 5423-31.
59. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999; 5: 29-33.
60. Abu-Amer Y, Dowdy SF, Ross FP, Clohisy JC, Teitelbaum SL. TAT fusion proteins containing tyrosine 42-deleted IkappaBalpha arrest osteoclastogenesis. J Biol Chem 2001; 276: 30499-503.
61. Kasim V, Miyagishi M, Taira K. Control of siRNA expression using the Cre-loxP recombination system. Nucleic Acids Res 2004; 32: e66.
62. Zender L, Kuhnel F, Kock R, Manus M, Kubicka S. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 2002; 9: 489-96.
63. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, el al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27KipI induces cell migration. Nat Med 1998; 4: 1449-52.
64. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 200 1; 19: 1173-6.
65. Yuan J, Kramer A, Eckerdt F, Kaufmann M, Strebbardt K. Efficient internalization of the polo-box of polo-like kinase I fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res 2002; 62: 4186-90.
66. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide. PLoS Biol 2004; 2: E36.
67. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, et al, Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002; 109: 1463-70.
68. Klein D, Ribeiro MM, Mendoza V, Jayaraman S, Kenyon NS, Pileggi A, el al. Delivery of BcI-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets. Biochem Biophys Res Commun 2004; 323: 473-8.
69. Noguchi H, Matsushita M, Okitsu T, Moriwaki A, Tomizawa K, Kang S, et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med 2004; 10: 305-9.
70. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, et al. Possible novel therapy for diabetes with cel-permeable JNK-inhibitory peptide. Nat Mod 2004, 10: 1128-32.
71. Borsello T, Clarke PG, Hirt L, Vercelli A, Repiti M, Schorderet DF, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003; 9: 1180-6.
72. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura L et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction w vivo. Nat Meld 2004; 10: 617-24.
73. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000; 289: 1550-4.
74. Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov Today 2002; 7: 1138-43.
75. Hong FD, Clayman GL. Isolation of a poptide for targeted drug delivery into human head and neck solid tumors. Cancer Res 2000; 60: 6551-6.
76. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, el al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Nad Acad Sci USA 2004; 101: 9381-6.
77. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002; 8: 751-5.
78. Arap W, Pasqualini R, Ruoslahti E Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80.
79. Sawada M, Hayes P, Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding, domain of Ku7O. Nat Cell Biol 2003; 5: 352-7.
80. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S. Ku7O suppresses the apoptotic translocalion of Bax to mitochondria. Nat Cell Biol 2003; 5: 320-9.
81. Yoshida T, Tomioka I, Nagahara T, Holyst T, Sawada M, Hayes P, et al. Bax-inhibiting peptide derived from mouse and rat Ku70. Biochem Biophys Res Commun 2004; 321: 961-6.
82. Crooke ST. Progress in antisense technology. Annu Rev, Med 2004; 55:61-95.
83. Dias N, Stein CA. Antisense oligonucleotides: basic oncepts and mechanisms. Mol Cancer Ther 2002; 1: 347-55.
84. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-44.
85. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254: 1497-500.
86. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993; 365: 566-8.
87. Pooga M, Soomets U, Hällbrink M, Valkna A, Saar K, Rezaei K, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 1998; 16: 857-61.
88. Fischer PM, Krausz E, Lane DP. Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjug Chem 2001; 12: 825-41.
89. Tung CH, Stein S. Preparation and applications of peptide-oligonucleotide conjugates. Bioconjug Chem 2000; 11: 605-18.
90. Allinquant B, Hantraye P, Mailleux P, Moya K, Bouillot C, Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J Cell Biol 1995; 128- 919-27.
91. Kilk K, Elmquist A, Saar K, Pooga M, Land T, Bartfai T, et al. Targeting of antisense PNA oligomers to human galanin receptor type 1 mRNA; Neuropeptides 2004; 38: 316-24.
92. Kaushik N, Basu A, Palumbo P, Myers RL, Pandey VN. Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol 2002; 76: 3881-91.
93. Östenson CG, Sandberg-Nordqvist AC, Chen J, Hällbrilik M, Rotin D, Langel Ü, et al. Overexpression of protein-tyrosine phosphatase PTP sigma is linked to impaired glucose-induced insulin secretion in hereditary diabetic Goto-Kakizaki rats. Biochem Biophys Res Commun 2002; 291: 945-50.
94. Efimov V, Choob M, Buryakova A, Phelan D, Chakhmakhcheva O. PNA-related oligonucleotide mimics and their evaluation for nucleic acid hybridization studies and analysis. Nucleosides Nucleotides Nucleic Acids 200 1; 20: 419-28.
95. Morris MC, Chaloin L, Choob M, Archdeacon J, Heitz F, Divita G. Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression. Gene Ther 2004; 11: 757-64.
96. Nielsen PE, Koppelhus U, Beck F. In: Nielsen PE ed., Pseudo-Peptides in Drug Discovery, WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany 2004; pp. 153-192.
97. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737-47.
98. Lee LK, Roth CM. Antisense technology in molecular and cellular bioengineering. Curr Opin Biotechnol 2003; 14: 505-11.
99. Chin YL, Ali A, Chu CY, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004; 11: 1165-75.
100. Muratovska. A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004; 558: 63-8.
101. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptidc-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003; 31: 2717-24.
102. Fisher L, Soomets U, Cortes Toro V, Chilton L, Jiang Y, Langel Ü, et al. Cellular delivery of a double-stranded oligonucleotide NFkappaB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide. Gene Ther 2004; 11: 1264-72.
103. Boussif O, LezouaIc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-301.
104. Remy-Kristensen A, Clamme JP, Vuilleumier C, Kuhry JG, Mely Y. Role of endocytosis in the transfection of L929 fibroblasts by polyethylenimine/DNA complexes. Biochim Biophys Acta 2001; 1514:21-32.
105. Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J Control Release 2001; 73: 401-16.
106. Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 1999; 6: 595-605.
107. Brandén LJ, Mohamed AJ, Smith CI. A peptide nucleic acid-nuclear localization signal fiision that mediates nuclear transport of DNA. Nat Biotechnol 1999; 17: 784-7.
108. Ogris M, Carlisle RC, Bettinger T, Seymour LW. Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors. J Biol Chem 2001; 276: 47550-5.
109. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D'Souza GG. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 2003; 100: 1972-7.
110. Tung CH, Mueller S, Weissleder R. Novel branching membrane translocational peptide as gene delivery vector. Bioorg Med Chem 2002; 10: 3609-14.
111. Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 2003; 278: 11411-8.
112. Morris MC, Chaloin L, Mery J, Heitz F, Divita G. A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res 1999; 27: 3510-7.
113. Krauss U, Muller M, Stahl M, Beck-Sickinger AG. In vitro gene delivery by a novel human calcitonin (hCT)-derived carrier peptide. Bioorg Med Chem Lett 2004; 14: 51-4.
114. Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, Brasseur R, el al. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther 2002; 5: 104-14.
115. Gottschalk S, Sparrow JT, Hauer J, Mims MP, Leland FE, Woo SL, et al. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther 1996; 3: 48-57.
116. Morris MC, Chaloin L, Heitz F, Divita G. Translocating peptides and proteins and their use for gene delivery. Curr Opin Biotechnol 2000; 11: 461-6.
117. Kilk Y,, Magzoub M, Poop M Eriksson LE, Langel Ü, Gräslund A. Cellular internalization of a cargo complex with a novel peptide derived from the third helix of the islet-1 homeodomain. Comparison with the penetratin peptide. Bioconjug Chem 2001; 12:911-6.
118. Schmidt MC, Rothen-Rutishauser B, Rist B, Beck-Sickinger A, Wunderli-Allenspach H, Rubas W, et al. Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry 1998; 37: 16582-90.
119. Lundberg P, Magzoub M, Lindberg M, Häillbrink M, Jarvet J, Eriksson LE, et al. Cell membrane translocation of the N-terminal (1 -28) part of the prion protein. Biochem Biophys Res Common 2002; 299: 85-90.
120. Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka FC, Jr. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 1997; 36: 3008-17.
121. Lissy NA, Davis PK Irwin M, Kaelin WG, Dowdy SF. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 2000; 407: 642-5.
122. Snyder EL, Meade BR, Dowdy SF. Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor ftinction. J Control Release 2003; 91: 45-51.
123. Fahraeus R, Paramio JM, Ball KL, Lain S, Lane DP. Inhibition of pRb phosphorylation and cell-cycle psogression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 1996; 6: 84-91.
124. Herbert TP, Fahraeus R, Prescott A, Lane DP, Proud CG. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 2000; 10: 793-6.
125. Aizawa H, Wakatsuki S, Ishii A, Moriyama K, Sasaki Y, Ohashi K, et al. Phosphorylation of cofilin by LIM-kinase is necessary for semaphorin 3A-induced growth cone collapse. Nat Neurosci 2001; 4: 367-73.
126. Oehlke J, Wallukat G, Wolf Y, Ehrlich A, Wiesner B, Berger H, et al. Enhancement of intracellular concentration and biological activity of PNA after conjugation with a cell-penetrating synthetic model peptide. Eur J Biochem 2004; 271: 3043-9.
127. Moulton HK Hase MC, Smith KM, Iversen PL. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 2003; 13: 31-43.
128. Fisher AA, Ye D, Sergueev DS, Fisher MH, Shaw BR, Juliano RL. Evaluating the specificity of antisense oligonuclootide conjugates. A DNA array analysis. J Biol Chem 2002; 277: 22980-4.
129. Cutrona G, Carpaneto EM, Ulivi M, Roncella S, Landt O, Ferrarini M, et al. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol 2000; 18: 300-3.
130. Smith CA, Hinman CL. A cyclic peptide, LIAD3, induces early sips of apoptosis in human leukemic T-cell lines. J Biochem Mol Toxicol 2004; 18: 204-20.
131. Poop M, Kut C, Kihlmark M, Hällbrink K Fernaeus S, Raid R, et al. Cellular translocation of proteins by transportan. Faserb J 200 1; 15:1451-3.
132. Beletskii A, Hong YK, Pehrson J, Egbolm M, Strauss WM. PNA interference mapping demonstrates functional domains in the noncoding RNA Xist. Proc Nad Acad Sial USA 2001; 98- 9215-20.
133. Bleeker-Rovers CP, Boerman OC, Rennen HJ, Corstens FK Oyen WJ. Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Design 2004; 10(24): 2935-50.
134. Dyba M, Tarasova NI, Michejda CJ. Small molecule toxins targeting tumor receptors. Curr Pharm Design 2004, 10(19): 2311-34.
135. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Design 2004; 10(13): 1469-92.